JP2012531411A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012531411A5 JP2012531411A5 JP2012517509A JP2012517509A JP2012531411A5 JP 2012531411 A5 JP2012531411 A5 JP 2012531411A5 JP 2012517509 A JP2012517509 A JP 2012517509A JP 2012517509 A JP2012517509 A JP 2012517509A JP 2012531411 A5 JP2012531411 A5 JP 2012531411A5
- Authority
- JP
- Japan
- Prior art keywords
- tocotrienol
- effective amount
- composition
- therapeutically effective
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011731 tocotrienol Substances 0.000 claims description 59
- 229930003802 tocotrienol Natural products 0.000 claims description 55
- 235000019148 tocotrienols Nutrition 0.000 claims description 55
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims description 50
- RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 claims description 48
- 229940064063 alpha tocotrienol Drugs 0.000 claims description 44
- RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 claims description 44
- 235000019145 α-tocotrienol Nutrition 0.000 claims description 44
- 239000011730 α-tocotrienol Substances 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 39
- 208000029560 autism spectrum disease Diseases 0.000 claims description 36
- 208000012202 Pervasive developmental disease Diseases 0.000 claims description 31
- 235000013305 food Nutrition 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 235000005911 diet Nutrition 0.000 claims description 12
- 230000000378 dietary effect Effects 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 9
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 9
- 229910019142 PO4 Inorganic materials 0.000 claims description 9
- 229940009098 aspartate Drugs 0.000 claims description 9
- 229930195712 glutamate Natural products 0.000 claims description 9
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 9
- 235000001968 nicotinic acid Nutrition 0.000 claims description 9
- 239000011664 nicotinic acid Substances 0.000 claims description 9
- 239000010452 phosphate Substances 0.000 claims description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 9
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 9
- OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Natural products OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 claims description 8
- 208000024825 childhood disintegrative disease Diseases 0.000 claims description 6
- 208000036640 Asperger disease Diseases 0.000 claims description 5
- 201000006062 Asperger syndrome Diseases 0.000 claims description 5
- 206010003805 Autism Diseases 0.000 claims description 5
- 208000020706 Autistic disease Diseases 0.000 claims description 5
- 208000006289 Rett Syndrome Diseases 0.000 claims description 5
- 208000036353 Rett disease Diseases 0.000 claims description 5
- 150000003612 tocotrienol derivatives Chemical class 0.000 claims description 5
- FGYKUFVNYVMTAM-UHFFFAOYSA-N (R)-2,5,8-trimethyl-2-(4,8,12-trimethyl-trideca-3t,7t,11-trienyl)-chroman-6-ol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-UHFFFAOYSA-N 0.000 claims description 4
- ODADKLYLWWCHNB-UHFFFAOYSA-N 2R-delta-tocotrienol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-UHFFFAOYSA-N 0.000 claims description 4
- FGYKUFVNYVMTAM-YMCDKREISA-N beta-Tocotrienol Natural products Oc1c(C)c2c(c(C)c1)O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CC2 FGYKUFVNYVMTAM-YMCDKREISA-N 0.000 claims description 4
- BTNBMQIHCRIGOU-UHFFFAOYSA-N delta-tocotrienol Natural products CC(=CCCC(=CCCC(=CCCOC1(C)CCc2cc(O)cc(C)c2O1)C)C)C BTNBMQIHCRIGOU-UHFFFAOYSA-N 0.000 claims description 4
- FGYKUFVNYVMTAM-MUUNZHRXSA-N epsilon-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-MUUNZHRXSA-N 0.000 claims description 4
- OTXNTMVVOOBZCV-YMCDKREISA-N gamma-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CCc2c1 OTXNTMVVOOBZCV-YMCDKREISA-N 0.000 claims description 4
- 235000012054 meals Nutrition 0.000 claims description 4
- -1 tocotrienol ester Chemical class 0.000 claims description 4
- 239000011723 β-tocotrienol Substances 0.000 claims description 4
- 235000019151 β-tocotrienol Nutrition 0.000 claims description 4
- FGYKUFVNYVMTAM-WAZJVIJMSA-N β-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-WAZJVIJMSA-N 0.000 claims description 4
- 239000011722 γ-tocotrienol Substances 0.000 claims description 4
- 235000019150 γ-tocotrienol Nutrition 0.000 claims description 4
- OTXNTMVVOOBZCV-WAZJVIJMSA-N γ-tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-WAZJVIJMSA-N 0.000 claims description 4
- 239000011729 δ-tocotrienol Substances 0.000 claims description 4
- 235000019144 δ-tocotrienol Nutrition 0.000 claims description 4
- ODADKLYLWWCHNB-LDYBVBFYSA-N δ-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-LDYBVBFYSA-N 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 150000003773 α-tocotrienols Polymers 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 208000035478 Interatrial communication Diseases 0.000 description 2
- 206010003664 atrial septal defect Diseases 0.000 description 2
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26962709P | 2009-06-25 | 2009-06-25 | |
| US61/269,627 | 2009-06-25 | ||
| PCT/US2010/025447 WO2010151348A1 (en) | 2009-06-25 | 2010-02-25 | Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012531411A JP2012531411A (ja) | 2012-12-10 |
| JP2012531411A5 true JP2012531411A5 (cg-RX-API-DMAC7.html) | 2013-04-11 |
Family
ID=43386829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012517509A Pending JP2012531411A (ja) | 2009-06-25 | 2010-02-25 | トコトリエノールまたはトコトリエノール濃縮抽出物を用いた広汎性発達障害の処置 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20120122969A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2445519A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2012531411A (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI1011776A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2765771A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201200054A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2011013558A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010151348A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005033093A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
| DK2471530T3 (en) * | 2005-06-01 | 2017-04-10 | Edison Pharmaceuticals Inc | REDOXACTIVE THERAPEUTIC AGENTS FOR THE TREATMENT OF MITOCONDARY DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS |
| EP1986636B1 (en) | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| HUE028502T2 (en) | 2007-11-06 | 2016-12-28 | Edison Pharmaceuticals Inc | 4- (P-Quinonyl) -2-hydroxybutanamide derivatives for the treatment of mitochondrial diseases |
| EP2237664A4 (en) * | 2008-01-08 | 2013-05-22 | Edison Pharmaceuticals Inc | (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES |
| US8716527B2 (en) | 2008-03-05 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases |
| US8716486B2 (en) * | 2008-06-25 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| LT3827815T (lt) | 2008-09-10 | 2023-10-10 | Ptc Therapeutics, Inc. | Psichologinių raidos sutrikimų gydymas oksidacijos redukcijos atžvilgiu aktyviais vaistais |
| US10039722B2 (en) | 2008-10-14 | 2018-08-07 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| ES2553557T3 (es) | 2008-10-28 | 2015-12-10 | Edison Pharmaceuticals, Inc. | Proceso para la producción de alfa-tocotrienol y derivados |
| HUE037574T2 (hu) | 2009-04-28 | 2018-09-28 | Bioelectron Tech Corp | Leber-féle örökletes optikus neuropátia és domináns optikus atrofia kezelése tokotrienol kinonokkal |
| US20110207828A1 (en) * | 2009-08-26 | 2011-08-25 | Miller Guy M | Methods for the prevention and treatment of cerebral ischemia |
| WO2013013078A1 (en) | 2011-07-19 | 2013-01-24 | Edison Pharmeceuticals, Inc. | Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
| JP6460998B2 (ja) * | 2012-11-13 | 2019-01-30 | インビクタス バイオテクノロジー プロプライエタリー リミテッド | トコトリエノールの経粘膜送達 |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| WO2015013285A2 (en) * | 2013-07-22 | 2015-01-29 | Ohio State Innovation Foundation | Methods for reducing the occurrence of hot flashes |
| NZ733528A (en) | 2014-12-16 | 2021-07-30 | Ptc Therapeutics Inc | Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide |
| JP7117241B2 (ja) | 2015-12-16 | 2022-08-12 | ピーティーシー セラピューティクス， インコーポレイテッド | 混合されたトコール組成物からアルファ－トコトリエノールを富化するための改良された方法 |
| CA3008849A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| HUE066196T2 (hu) | 2018-10-17 | 2024-07-28 | Ptc Therapeutics Inc | 2,3,5-trimetil-6-nonilciklohexa-2,5-dién-1,4-dion alfa-szinukleinopátiák, tauopátiák és egyéb rendellenességek szuppresszálására és kezelésére |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| US20220214358A1 (en) * | 2019-04-05 | 2022-07-07 | Arizona Board Of Regents On Behalf Of Arizona State University | Diagnostic for childhood risk of autism spectrum disorder |
| MY196888A (en) * | 2019-11-19 | 2023-05-08 | Hovid Berhad | A composition for managing cadasil |
| EP3981397A1 (en) * | 2020-10-08 | 2022-04-13 | Global Scientific | Tocotrienols derivates, methods and uses thereof |
| CA3225266A1 (en) | 2021-07-08 | 2023-01-12 | Swathi PINNAMANENI | Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0788376B2 (ja) | 1986-09-02 | 1995-09-27 | エーザイ株式会社 | 光学活性α−トコトリエノ−ルの製造方法 |
| JP2685785B2 (ja) | 1988-03-11 | 1997-12-03 | エーザイ株式会社 | 光学活性α−トコトリエノールの製造方法 |
| JPH029875A (ja) | 1988-03-16 | 1990-01-12 | Bio Ind Kyokai | トコフェロール及びトコトリエノールの製造方法 |
| US5157132A (en) | 1990-05-18 | 1992-10-20 | Carotech Associates | Integrated process for recovery of carotenoids and tocotrienols from oil |
| EP0543417A1 (en) | 1991-11-22 | 1993-05-26 | Lipogenics, Incorporated | Tocotrienols and tocotrienol-like compounds and methods for their use |
| US20030134028A1 (en) * | 1995-06-01 | 2003-07-17 | Lipton, Division Of Conopco, Inc. | Fat based food products |
| JP2002501915A (ja) | 1998-01-29 | 2002-01-22 | イーストマン ケミカル カンパニー | トコール含有混合物からのトコールの分離方法 |
| US6472378B2 (en) | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
| US6187811B1 (en) * | 1998-10-28 | 2001-02-13 | Lipogenics, Inc. | Methods for treating benign prostatic hyperplasia using tocotrienols |
| WO2000027393A1 (en) | 1998-11-06 | 2000-05-18 | Fuji Chemical Industry Co., Ltd. | Powders containing tocotrienols, process for producing the same and tablets prepared by compression molding the same |
| US6761903B2 (en) * | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| US6395915B1 (en) | 1999-09-10 | 2002-05-28 | Technikrom, Inc. | Method for producing purified tocotrienols and tocopherols using liquid chromatography |
| MY127451A (en) | 1999-11-04 | 2006-12-29 | Malaysian Palm Oil Board | A method of chromatographic isolation for vitamin e isomers |
| US20030206972A1 (en) * | 2000-10-13 | 2003-11-06 | Babish John G. | Compositions containing carotenoids and tocotrienols and having synergistic antioxidant effect |
| US20020155170A1 (en) * | 2000-11-30 | 2002-10-24 | Walsh William John | Nutrient supplements and methods for treating autism and for preventing the onset of autism |
| US6838104B2 (en) | 2000-12-20 | 2005-01-04 | Archer Daniels Midland Company | Process for the production of tocotrienols |
| US7217133B2 (en) * | 2002-04-04 | 2007-05-15 | Jeanine Thomas | Method for treating pervasive development disorder |
| AT414082B (de) * | 2002-05-03 | 2006-09-15 | Vis Vitalis Lizenz & Handels | Verfahren zur herstellung von tocotrienol-angereicherten präparationen |
| WO2005035491A2 (en) | 2003-10-10 | 2005-04-21 | Yasoo Health, Inc. | PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS FROM 2- VINYLCHROMANE COMPOUND |
| MXPA06009529A (es) | 2004-02-23 | 2007-04-10 | Texas A & M Univ Sys | Composiciones antioxidantes y metodos para el uso de las mismas. |
| US10300034B2 (en) * | 2007-02-22 | 2019-05-28 | Children's Hospital Of Oakland Research Institute | Fatty acid formulations and methods of use thereof |
| KR101481197B1 (ko) | 2007-05-24 | 2015-01-09 | 로더스 크로클란 비.브이. | 토코페롤 및 토코트리에놀을 함유하는 조성물의 제조방법 |
-
2010
- 2010-02-25 US US13/380,802 patent/US20120122969A1/en not_active Abandoned
- 2010-02-25 WO PCT/US2010/025447 patent/WO2010151348A1/en not_active Ceased
- 2010-02-25 JP JP2012517509A patent/JP2012531411A/ja active Pending
- 2010-02-25 CA CA2765771A patent/CA2765771A1/en not_active Abandoned
- 2010-02-25 MX MX2011013558A patent/MX2011013558A/es not_active Application Discontinuation
- 2010-02-25 EA EA201200054A patent/EA201200054A1/ru unknown
- 2010-02-25 EP EP10792467A patent/EP2445519A4/en not_active Withdrawn
- 2010-02-25 BR BRPI1011776A patent/BRPI1011776A2/pt not_active IP Right Cessation
- 2010-02-25 EP EP13161401.8A patent/EP2609921A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012531411A5 (cg-RX-API-DMAC7.html) | ||
| JP2014528914A5 (cg-RX-API-DMAC7.html) | ||
| US9101649B2 (en) | Phenolic compositions derived from apple skin and uses thereof | |
| JP6265624B2 (ja) | ルリコナゾール含有外用医薬組成物 | |
| ES2341717T3 (es) | Composicion farmaceutica que comprende, entre otros, vitamina c, magnesio y extracto de te verde para retardar las enfermedades cardiovasculares (proliferacion de smc). | |
| Yamagata et al. | Epigallocatechin-3-gallate inhibits VCAM-1 expression and apoptosis induction associated with LC3 expressions in TNFα-stimulated human endothelial cells | |
| BR112013027028A2 (pt) | preparo de gadobutrol de alta pureza | |
| JP2014519525A5 (cg-RX-API-DMAC7.html) | ||
| TW200718418A (en) | Cannabinoid active pharmaceutical ingredient for improved dosage forms | |
| JP2010525050A5 (cg-RX-API-DMAC7.html) | ||
| JP2016516040A5 (cg-RX-API-DMAC7.html) | ||
| EP3146340B1 (en) | Methods of preparing materials with ammonia oxidizing bacteria and testing materials for ammonia oxidizing bacteria | |
| WO2010015665A3 (en) | Parenteral composition comprising microspheres with a diameter between 10 and 20 microns | |
| NZ591810A (en) | Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid | |
| MY143795A (en) | Tetrahydropyridoindole derivatives | |
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| BR112014018795A2 (pt) | derivados de 1h-pirrolo[2,3-b]piridina e seu uso como inibidores de cinase | |
| BR112014024964A8 (pt) | formulação compósita compreendendo comprimido esferoidal de multi-unidade (must) encapsulado em cápsula dura e método para sua preparação | |
| JP2001507363A (ja) | イソプレノイド類とスタチン類との組合せによる腫瘍成長抑制方法 | |
| GEP20146177B (en) | Pyrazole compounds as crth2 antagonists | |
| NZ734152A (en) | Compounds, compositions and methods useful for cholesterol mobilisation | |
| TNSN08348A1 (en) | Antibiotic compositions of modified release and process of production thereof | |
| Kumar et al. | Preferential radiation sensitization of prostate cancer in nude mice by nutraceutical antioxidant γ-tocotrienol | |
| BR112015027440A2 (pt) | DERIVADO DE [1,2,4]TRIAZOL[4,3-a]PIRIDINA, MÉTODO DE PREPA-RAÇÃO OU APLICAÇÃO MÉDICA DO DERIVADO | |
| GT201300144A (es) | Composiciones farmaceuticas |